- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02099149
Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days
July 23, 2014 updated by: Novartis
Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.
Compare anticapsular antibody levels against Group B Streptococcus at delivery in mothers and their infants who develop disease versus those who do not.
Use this comparison to establish antibody levels associated with reductions in risk of GBS disease in infants aged less than 90 days.
Study Overview
Status
Withdrawn
Conditions
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gauteng
-
Soweto, Gauteng, South Africa, 2013
- Respiratory and Meningeal Pathogen Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Pregnant women aged 18 years or older attending for antenatal care or delivery at 3 academic hospital centers in the Johannesburg area and the antenatal clinics serving those hospital centers.
Description
Inclusion Criteria:
- Pregnant women attending participating community/hospital antenatal clinics and/or delivering at participating delivery centers.
- Subjects aged ≥18 years.
- Able to understand and comply with planned study procedures.
- Provides written informed consent.
Exclusion Criteria:
- Refuses to consent to study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Controls
Infants born to GBS colonized mother who do not develop GBS disease
|
Cases
Infants with culture confirmed GBS disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early onset Group B Streptococcus Disease due to serotypes Ia or III
Time Frame: 0-6 days
|
Risk of early onset Group B Streptococcus disease (due to serotypes Ia or III) with respect to maternal or newborn anticapsular antibody levels at delivery
|
0-6 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Late onset Group B Streptococcus Disease due to serotype III
Time Frame: 7-90 days
|
Risk of late onset Group B Streptococcus disease (due to serotypes III) with respect to maternal or newborn anticapsular antibody levels at delivery
|
7-90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Anticipated)
August 1, 2015
Study Completion (Anticipated)
August 1, 2015
Study Registration Dates
First Submitted
March 25, 2014
First Submitted That Met QC Criteria
March 27, 2014
First Posted (Estimate)
March 28, 2014
Study Record Updates
Last Update Posted (Estimate)
July 24, 2014
Last Update Submitted That Met QC Criteria
July 23, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- V98_28OB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Group B Streptococcus Disease
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompletedInvasive Group B Streptococcus (GBS) DiseaseSwitzerland
-
University of Witwatersrand, South AfricaNovartis VaccinesCompleted
-
Novartis VaccinesCompletedGroup B Streptococcus (GBS) DiseaseSwitzerland
-
NovartisNovartis VaccinesCompletedA Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS VaccineGroup B Streptococcus (GBS) DiseaseSwitzerland
-
University of OxfordWellcome TrustCompletedStreptococcus Agalactiae (Streptococcus Group B)Kenya
-
Unity Health TorontoCompleted
-
Novartis VaccinesGlaxoSmithKlineCompletedGroup B StreptococcusBelgium
-
George Washington UniversityCompletedGroup B StreptococcusUnited States
-
William Beaumont HospitalsTerminatedGroup B StreptococcusUnited States